An Evaluation of the Pharmacokinetics, Pharmacodynamics, and Dialyzability of Verapamil in Chronic Hemodialysis Patients

James Hanyok(Daiichi Sankyo (United States)), Mark W. Izard(Hartford Hospital), Jeffrey Kluger(Hartford Hospital), Moses S.S. Chow(Hartford Hospital)
The Journal of Clinical Pharmacology
September 1, 1988
10.1002/j.1552-4604.1988.tb03224.x
Cited by 18

Related Papers

Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.2k
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)
|American Heart Journal|2010|482
Effect of ACAT Inhibition on the Progression of Coronary Atherosclerosis
|New England Journal of Medicine|2006|397
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|390
Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled study
|American Heart Journal|1995|121